# Ampullary Carcinoma: Prognostic Factors and a Literature Review

**Authors:** Ivánia Furtado, Nuno Gião, Ana Gonçalves, Emanuel Vigia, Mariana Sardinha, João Boavida Ferreira

PMC · DOI: 10.3390/cancers18040707 · 2026-02-22

## TL;DR

This study identifies surgical resection margin as a key factor affecting survival in ampullary carcinoma, a rare cancer with limited treatment guidelines.

## Contribution

The study identifies R1 resection margin as the only independent prognostic factor for recurrence-free survival in ampullary carcinoma.

## Key findings

- R1 resection margin was independently associated with shorter recurrence-free survival in ampullary carcinoma patients.
- No clinicopathological factor was independently linked to overall survival in resected ampullary carcinoma cases.
- Adjuvant therapy showed potential benefit in exploratory analyses but lacked significance in unadjusted models.

## Abstract

Ampullary carcinoma is a rare cancer that is largely underrepresented in prospective clinical trials. As a result, treatment strategies are often extrapolated from other gastrointestinal tumors, and clear criteria for selecting patients who may benefit from adjuvant therapy are lacking. In this retrospective observational study, we analyzed clinical data from patients with ampullary carcinoma to explore factors associated with survival outcomes. We also reviewed the existing medical literature to place our findings in context. Advanced tumor stage, lymph node involvement, lymphovascular/perineural invasion, high tumor grade, and positive resection margins were associated with worse outcomes; however, only positive resection margins were independently associated with shorter recurrence-free survival, and no factor was independently linked to overall survival. While adjuvant therapy may have a role, improved patient selection is needed to maximize benefit. These findings highlight the need for better risk stratification strategies and the importance of multidisciplinary decision-making in managing this uncommon disease.

Background/Objectives: Ampullary carcinoma (AC) is a rare gastrointestinal malignancy arising from the ampullary complex, encompassing intestinal, pancreaticobiliary, and mixed subtypes with distinct biological behaviors. Surgery is the only potentially curative treatment, yet relapse occurs in more than half of patients. Due to the scarcity of AC-specific prospective trials, treatment guidelines are largely extrapolated from other gastrointestinal cancers. This study aimed to characterize the clinicopathological features, treatment approaches, and outcomes of AC and to identify potential prognostic factors in a single-center cohort. Methods: We retrospectively analyzed 106 patients diagnosed with AC between January 2015 and December 2023 to characterize clinicopathological features, treatment approaches, and survival outcomes, and to explore potential prognostic factors. Kaplan–Meier analysis was used to estimate recurrence-free survival (RFS) and overall survival (OS), while prognostic factors were assessed using univariate and multivariable Cox regression models. Results: Most patients presented with resectable disease and underwent pancreaticoduodenectomy (96.2%). The predominant histological subtype was pancreaticobiliary (45.3%). In localized disease, median RFS and OS were not reached, with 36-month RFS and OS rates of 68.1% (95% CI, 59.2–78.3) and 70.1% (95% CI, 61.1–80.3), respectively. In univariate analyses, adverse prognostic factors for both RFS and OS included the advanced T TNM category, nodal involvement, lymphovascular invasion, perineural invasion, high-grade histology, and R1 resection margins; however, only R1 resection margin remained independently associated with shorter RFS in the multivariate analysis (HR 2.5, 95% CI 1.02–5.94, p = 0.046). Survival outcomes did not differ significantly according to histological subtype. Exploratory adjusted analyses accounting for nodal status and surgical resection margin suggested an association between adjuvant therapy and improved survival, while unadjusted analyses showed no significant associations. Median OS for metastatic patients was 13.6 months. Discussion/Conclusion: R1 resection margin emerged as the only independent prognostic factor for RFS, with no independent association with OS, in resected AC. These findings highlight the importance of surgical margin optimization, high-quality pathological assessment, and multidisciplinary management in routine clinical practice.

## Linked entities

- **Diseases:** ampullary carcinoma (MONDO:0017590)

## Full-text entities

- **Genes:** MUC5AC (mucin 5AC, oligomeric mucus/gel-forming) [NCBI Gene 4586] {aka MUC5, TBM, leB, mucin}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583] {aka MLP, MUC-2, SMUC}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}
- **Diseases:** GI malignancies (MESH:D005770), biliary obstruction (MESH:D001658), lymph node (MESH:D000072717), lymph node metastases (MESH:D008207), Obstructive jaundice (MESH:D041781), poorly cohesive cell carcinoma (MESH:D002280), death (MESH:D003643), colorectal cancer (MESH:D015179), mOS (MESH:D011475), grade 3 (MESH:D008224), metastases (MESH:D009362), T3-T4 tumors (MESH:D005067), jaundice (MESH:D007565), T3 (MESH:C537047), neuroendocrine tumors (MESH:D018358), Pancreatic Cancer (MESH:D010190), injury to (MESH:D014947), disease (MESH:D004194), node (MESH:D012804), biliary tract cancer (MESH:D001661), undifferentiated carcinoma (MESH:D002277), medullary carcinoma (MESH:D018276), Cancer (MESH:D009369), adenocarcinoma (MESH:D000230)
- **Chemicals:** FOLFIRINOX (MESH:C000627770), larotrectinib (MESH:C000609083), Gemcitabine (MESH:D000093542), entrectinib (MESH:C000607349), cisplatin (MESH:D002945), CAPOX (-), FOLFOX (MESH:C410216), capecitabine (MESH:D000069287), pembrolizumab (MESH:C582435), leucovorin (MESH:D002955), 5-FU (MESH:D005472), GEMOX (MESH:C508870), oxaliplatin (MESH:D000077150), trastuzumab (MESH:D000068878), irinotecan (MESH:D000077146)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939735/full.md

---
Source: https://tomesphere.com/paper/PMC12939735